Windsor is cutting the number of officers available to enforce city bylaws as it restructures the department, according to their union. Windsor Mayor Drew Dilkens weighed in on the changes. The CBC's ...
LuxMare is a project completed this year by architecture office Mário Martins Atelier and which consists of two contemporary houses that complement one another while managing to maintain their ...
WOODLAND HILLS, Ca. The Los Angeles Rams made a bold move to acquire cornerback Trent McDuffie, and while many are weighing in on the trade, it's what the Rams do next that could be the determining ...
GameSpot may get a commission from retail offers. The Resident Evil series has a long history of struggling to find the right balance of horror and action, sometimes becoming massively successful and ...
Over the past decade, U.S. stocks have dominated international stocks in terms of both earnings growth and total returns. In 2026, international earnings growth is expected to be relatively comparable ...
A Crew Dragon spacecraft docked with the International Space Station on Valentine’s Day, and astronauts popped open the hatches at 5:14 pm ET (22:14 UTC) on Saturday evening. The arrival of four new ...
Manhattan’s Union Square is surrounded by a broad collection of historic, sometimes grand, structures. For passersby, an upward glance often reveals a panoply of magnificent carved masonry, ornately ...
Is it a sign of a good healthcare system when millions of people turn to a hallucinating robot for help? Reading time 2 minutes OpenAI just released a report about healthcare drawn from anonymized ...
Berkshire Hathaway provides an "anchor" to a portfolio with its massive war chest of cash. Apple's business is seeing accelerating momentum. These two stocks give investors access to both cutting-edge ...
Senior Pentagon officials are preparing a plan to downgrade several of the U.S. military’s major headquarters and shift the balance of power among its top generals, in a major consolidation sought by ...
Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease ...